Study of Hyperbaric Oxygen Therapy for Treating Post COVID-19 Syndrome Symptoms Including Fatigue

What this Trial Is About

Researchers are studying post COVID-19 condition, a syndrome affecting people who have recovered from COVID-19 but continue to experience symptoms like chronic fatigue, brain fog, stress, or anxiety for at least three months. This condition can seriously affect quality of life. The study aims to explore the feasibility of using hyperbaric oxygen therapy HBOT as a treatment for these symptoms and to prepare for a larger clinical trial to evaluate its impact. Participants will receive hyperbaric oxygen therapy using a medical-grade monoplace hyperbaric chamber. The treatment consists of 40 sessions, each lasting 90 minutes at 2 atmospheres, delivered daily from Monday to Friday over about eight weeks. Participants are randomly assigned to start the treatment immediately after referral or after a 60-day delay. The study will follow patients for 12 months from the start of treatment, with regular assessments. During the study, participants will complete questionnaires and undergo assessments at enrollment, at the start of treatment, four weeks after treatment begins, and every two months for a year. Researchers will track recruitment rates, adherence to the treatment protocol, patient satisfaction, and clinical outcomes related to fatigue and quality of life. This will help determine if a larger trial is feasible and effective in assessing HBOT for post COVID-19 symptoms.

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments